Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

OGT to Host Company Showcase at BioTrinity 2012

Published: Monday, April 23, 2012
Last Updated: Monday, April 23, 2012
Bookmark and Share
Seminar to discuss company’s biomarker accelerator strategy for optimizing drug and diagnostic development.

Oxford Gene Technology (OGT) will be discussing its biomarker discovery offering at the European Biopartnering and Investment Conference, BioTrinity, from 24th-26th April in Newbury, UK.

The conference will include a Company Showcase from OGT’s CEO, Dr Mike Evans, which takes place at 4.20 pm on Wednesday 25th April.

The talk will provide an overview of OGT’s corporate strategy, which has delivered significant and sustained revenue growth, with particular focus on the company’s Diagnostic Biomarkers business unit.

OGT Diagnostic Biomarkers utilizes proprietary next generation technologies to identify informative biomarkers for early-stage detection of cancer and autoimmune disease.

Through a combination of the implementation of a unique Biomarker Accelerator Strategy and in-house discovery, OGT is building a rich patent-protected portfolio of promising biomarkers for a number of diseases where there are clear clinical needs and markets for improved diagnostic tests.

Details of this strategy and OGT’s additional biomarker discovery and validation services will be given in the presentation.

In a recent example of OGT’s Biomarker Accelerator Strategy, OGT entered into an exclusive licensing deal with Inven2, the technology transfer office at Oslo University Hospital and the University of Oslo.

Using 12 highly promising colorectal cancer tissue biomarkers developed at Oslo University Hospital, OGT now has an exclusive license to commercialize any resulting test developed with the biomarkers.

As a well-established private molecular diagnostics and clinical solutions company actively operating in 30 countries worldwide, OGT has a strong position in the large and rapidly growing molecular medicine market.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

OGT Appoints Dr Bob Holland as CMO
Company strengthens focus on cancer biomarkers.
Monday, October 21, 2013
Scientific News
Turning Skin Cells into Heart, Brain Cells
In a major breakthrough, scientists at the Gladstone Institutes transformed skin cells into heart cells and brain cells using a combination of chemicals.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Reprogramming Scorpion Venom
‘Twist of nature’ neutralizes toxin.
Tailoring a Suit for Tumor-Penetrating Cancer Meds
For more than a decade, biomedical researchers have been looking for better ways to deliver cancer-killing medication directly to tumors in the body.
Resurrecting an Abandoned Drug
Previously discarded drug shows promise in helping human cells in a lab dish fight off two different viruses.
Safer, Cheaper, Greener and More Efficient System for Organic Synthesis
The new medium not only supports organic synthesis it also produces considerably higher yields of product than pure organic solvents.
Fighting Prostate Cancer
Identifying the most promising compounds which can be used as medications for prostate cancer.
Collaboration to Develop Cancer Therapeutics
Major license agreement with Merck, enabled by Blavatnik Biomedical Accelerator, aims to develop therapy for most common form of acute leukemia.
Faster UVA Molecular Analysis Technology
There are people in the world – chemical engineers, astronomers, national defense scientists investigating an explosion – who need to know just what something is made of, down to the molecular level.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!